Developing Story
Novo Nordisk GLP-1 Patent Losses (Ozempic/Wegovy)
Novo Nordisk lost a key European patent covering Ozempic and Wegovy on October 9, 2026, when an EPO Board of Appeal revoked it despite an earlier preliminary opinion favoring Novo Nordisk. The ruling could open the door to earlier generic competition in the lucrative GLP-1 drug market.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
Novo Nordisk has lost another patent protecting its blockbuster GLP-1 drugs Ozempic and Wegovy. On October 9, 2026, EPO Board of Appeal 3.3.04 revoked a patent behind the drugs, reversing its own preliminary opinion (JUVE Patent, October 9). The decision is described as likely to have "far-reaching consequences" for market exclusivity, which can be worth six years or more to originator manufacturers, and correspondingly significant for generic drug companies seeking entry (JUVE Patent, October 9).
This follows a pattern of eroding patent protection around semaglutide-based products, which are among the best-selling drugs in the world. Continued patent losses could accelerate generic/biosimilar competition in the GLP-1 weight-loss and diabetes drug market, a multi-billion dollar category with major implications for Novo Nordisk's revenue, competitors like Eli Lilly, and global drug pricing dynamics.